Pfizer is winding down its Pfizer Ignite unit, a program designed to partner with and accelerate early‑stage startups, according to regulatory disclosures. The unit provided advisory services and access to Pfizer expertise for emerging biotech companies; the company will draw down operations and discontinue the initiative amid broader strategic shifts. Industry analysts view the closure as a sign that large pharmas are recalibrating how they engage with startups—moving from light‑touch incubators toward direct investment, focused alliances, or external venture‑backed partnerships. The move could reduce an available channel for small biotechs seeking in‑kind development support from a major pharma.